Charles River deepens its ties to Huntington's R&D with new deal

Charles River Laboratories ($CRL) has extended its partnership with CHDI Foundation, signing up for 5 more years of work spotlighting new treatments for Huntington's disease. The two have worked together since 2005 to discover novel drugs for the neurodegenerative disease, with Charles River providing a suite of preclinical services to CHDI's neuroscience experts. More

Suggested Articles

The platform uses wearables to continuously collect clinical data from study participants and applies machine learning to analyze the data.

St. Jude, Microsoft and DNAnexus have created a data-sharing and analysis platform to help accelerate pediatric cancer research.

Charles River partners with PathoQuest to offer clients NGS solutions for biologics viral contamination testing and cell-line genetic characterization.